Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Biotech and the flu pandemic

Biotechnology researchers are working to create new vaccination options to help stop the next big pandemic before it starts.  Join Dr. Targan of BIO’s BioBytes as he walks us through the current steps in vaccine production, and what biotechnology is doing to help create new vaccines in quicker timeframes to help meet the global demand (click link below for video). For those of you attending the 8th Annual BIO Investor Forum this week in San Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Panelists ponder when the window will open

Panelists in this afternoon’s business roundtable “Window Shopping – The Buyer’s Perspective on Today’s IPO Candidates” contemplated what it’s going to take to return to a vibrant IPO market. “What we need is public market examples of IPOs that are successful,” said Ashley Dombkowski, PhD, a managing director at MPM Capital. Daniel Lyons, PhD, CFA, an equity research analyst at Janus Capital added that having a lack of opportunities can make a company stand out Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Healthcare reform: sustaining biotech innovation in a new world

The Eighth Annual BIO Investor Forum kicked off today with a plenary session on health care reform with expert panelists who are entrenched in the day-to-day debate of the most comprehensive changes ever proposed for the U.S. health care system. Panelists agreed that it’s been a long and complicated debate and the end of year deadline is ambitious yet within the realm of possibility. Michelle Easton, a partner at Tarplin, Downs and Young, LLC, asserted that Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Guest blogger post: The Lure of Translational Research

As a breast cancer advocate, I am seduced by the lure of translational research and the promises of personalized medicine that will make the one size fits all approach to cancer treatment obsolete and possibly reduce over-treatment, toxicity, and treatment errors. I will be attending the BIO Technology Transfer Symposium and BIO Investor Forum next week and will look forward to hearing insights from biotech industry leaders. The Tech Transfer Symposium will address opportunities and Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

The Burrill Report Interview with Jim Greenwood

The Burrill Report’s Daniel Levine spoke with Jim Greenwood, president and CEO of BIO, about the upcoming Eighth Annual BIO Investor Forum’s opening plenary session on healthcare reform. Greenwood will be moderating the session, “Healthcare Reform: Sustaining Biotech Innovation in a New World.” Listen to the podcast.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,